These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10873111)

  • 81. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
    Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
    Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.
    Li Z; Li Q; Han L; Tian N; Liang Q; Li Y; Zhao X; Du C; Tian Y
    Oncol Rep; 2016 Feb; 35(2):1013-9. PubMed ID: 26718027
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cholera toxin triggers apoptosis in human lung cancer cell lines.
    Allam M; Bertrand R; Zhang-Sun G; Pappas J; Viallet J
    Cancer Res; 1997 Jul; 57(13):2615-8. PubMed ID: 9205066
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-κB in HL-60 cells.
    Shoji K; Tsubaki M; Yamazoe Y; Satou T; Itoh T; Kidera Y; Tanimori Y; Yanae M; Matsuda H; Taga A; Nakamura H; Nishida S
    Arch Pharm Res; 2011 Mar; 34(3):469-75. PubMed ID: 21547680
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Mol Cancer Ther; 2004 Feb; 3(2):169-78. PubMed ID: 14985457
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
    Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.
    Buck AC; Shen C; Schirrmeister H; Schmid-Kotsas A; Munzert G; Guhlmann A; Mehrke G; Klug N; Gross HJ; Bachem M; Reske SN
    Cancer Biother Radiopharm; 2002 Jun; 17(3):281-9. PubMed ID: 12136520
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
    Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
    Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
    Mercatante DR; Mohler JL; Kole R
    J Biol Chem; 2002 Dec; 277(51):49374-82. PubMed ID: 12381725
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Combining high-throughput screening of caspase activity with anti-apoptosis genes for development of robust CHO production cell lines.
    Dorai H; Ellis D; Keung YS; Campbell M; Zhuang M; Lin C; Betenbaugh MJ
    Biotechnol Prog; 2010; 26(5):1367-81. PubMed ID: 20945491
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells.
    Blanco-Colio LM; Justo P; Daehn I; Lorz C; Ortiz A; Egido J
    Kidney Int; 2003 Jul; 64(1):181-91. PubMed ID: 12787408
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Midregion PTHrP regulates Rip1 and caspase expression in MDA-MB231 breast cancer cells.
    Luparello C; Sirchia R; Lo Sasso B
    Breast Cancer Res Treat; 2008 Oct; 111(3):461-74. PubMed ID: 18030616
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Antisense therapy of hematologic malignancies.
    Cotter FE
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Use of antisense oligonucleotides for therapy. Manipulation of apoptosis inhibitors for destruction of lung cancer cells.
    Leech SH; Olie RA; Zangemeister-Wittke U
    Methods Mol Med; 2003; 75():655-70. PubMed ID: 12407770
    [No Abstract]   [Full Text] [Related]  

  • 97. Splicing and dicing apoptosis genes.
    Reed JC
    Nat Biotechnol; 1999 Nov; 17(11):1064-5. PubMed ID: 10545908
    [No Abstract]   [Full Text] [Related]  

  • 98. Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy.
    Schteingart DE; Benitez R; Bradford C; Narayan A; Wang S
    Anticancer Res; 2010 Dec; 30(12):4805-9. PubMed ID: 21187456
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
    Lo YL; Liu Y
    PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeted therapy against Bcl-2-related proteins in breast cancer cells.
    Emi M; Kim R; Tanabe K; Uchida Y; Toge T
    Breast Cancer Res; 2005; 7(6):R940-52. PubMed ID: 16280040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.